On December 16, 2024, TC BioPharm plc signed an At The Market Offering Agreement allowing sales of up to $14 million in American Depositary Shares via H.C. Wainwright & Co. The agreement enables selling shares on the Nasdaq and ends upon reaching the target amount or mutual termination.